• 1. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. Exclusive self-aligned β-phase PVDF films with abnormal piezoelectric coefficient prepared via phase inversion?
  N. Soin,D. Boyer,K. Prashanthi,S. Sharma,A. A. Narasimulu,J. Luo,T. H. Shah,E. Siores,T. Thundat Chem. Commun., 2015,51, 8257-8260
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

1,2-Dihydro-Betamethasone 17,21-Dipropionate (CAS No: 80163-83-3)

The compound 1,2-Dihydro-Betamethasone 17,21-Dipropionate (CAS No: 80163-83-3) is a synthetic corticosteroid with significant pharmacological properties. It belongs to the class of glucocorticoids, which are widely used in the treatment of inflammatory and immune-mediated conditions. This compound is derived from betamethasone, a well-known corticosteroid, and its structure incorporates dihydro and dipropionate modifications that influence its pharmacokinetic and pharmacodynamic profiles.

Recent studies have highlighted the importance of understanding the structural modifications in corticosteroids like 1,2-Dihydro-Betamethasone 17,21-Dipropionate. The dihydro group introduces a reduction at the C-1 and C-2 positions of the steroid nucleus, which is believed to enhance its stability and reduce potential side effects. Additionally, the dipropionate esterification at the 17 and 21 positions plays a critical role in modulating its lipophilicity and bioavailability. These structural features make it an attractive candidate for targeted therapeutic applications.

One of the most significant advancements in the study of CAS No: 80163-83-3 has been its application in localized therapies. Researchers have demonstrated that this compound exhibits potent anti-inflammatory effects when administered topically or via intra-articular injection. Its ability to suppress pro-inflammatory cytokines such as TNF-alpha and IL-6 has been extensively documented in preclinical models. Furthermore, clinical trials have shown that 1,2-Dihydro-Betamethasone 17,21-Dipropionate can effectively alleviate symptoms in conditions such as rheumatoid arthritis and allergic dermatitis without causing systemic side effects.

The pharmacokinetics of CAS No: 80163-83-3 have also been a focal point of recent investigations. Studies using advanced analytical techniques such as LC-MS/MS have revealed that this compound undergoes rapid absorption when administered locally but has a relatively short half-life due to efficient metabolic clearance. This characteristic makes it suitable for short-term therapeutic interventions where quick onset of action is required.

In terms of safety profiles, CAS No: 80163-83-3 has shown a favorable tolerance profile compared to traditional corticosteroids. Preclinical toxicology studies indicate minimal adrenal suppression and no significant hepatotoxicity at therapeutic doses. These findings are supported by ongoing clinical trials that are exploring its use in pediatric populations and patients with chronic inflammatory diseases.

Another area of emerging interest is the potential for combination therapies involving CAS No: 80163-83-3. Researchers are investigating its synergistic effects with biologic agents such as IL-4 receptor antagonists in treating refractory inflammatory conditions. Early results suggest that this approach could enhance therapeutic efficacy while minimizing adverse events.

In conclusion, CAS No: 80163-83-3 (1,2-Dihydro-Betamethasone 17,21-Dipropionate) represents a promising advancement in corticosteroid therapy. Its unique structural modifications confer advantageous pharmacokinetic and pharmacodynamic properties that make it a valuable tool in modern medicine. As research continues to uncover its full potential, this compound is poised to play a significant role in the treatment of various inflammatory and immune-mediated disorders.

• 514-36-3(Fludrocortisone acetate)
• 2529-45-5(flugestone 17-acetate)
• 23674-86-4(Difluprednate)
• 338-98-7(Isoflupredone acetate)
• 67-78-7(Triamcinolone 16,21-Diacetate)
• 127-31-1(Fludrocortisone)
• 1177-87-3(Dexamethasone acetate)
• 2152-44-5(Betamethasone valerate)
• 3801-06-7(Fluorometholone acetate)
• 987-24-6(betamethasone 21-acetate)